MétaCan
Menu
Back to cohort
Record W4408348202 · doi:10.1055/s-0045-1804283

Symptomatic skeletal events, health-related quality of life and pain in a phase III study of [177Lu]Lu-PSMA-617 in taxane-naive patients with PSMA-positive metastatic castration-resistant prostate cancer: Third interim analysis of PSMAfore

2025· article· en· W4408348202 on OpenAlexaff
Karim Fizazi, Michael J. Morris, N. Shore, K.N. Chi, M. J. Crosby, Johann S. de Bono, Ken Herrmann, Guilhem Roubaud, James Nagarajah, Mark T. Fleming, Brian Lewis, L. Nordquist, D.E. Castellano Gauna, Natalie Carnahan, Samson Ghebremariam, Marianna Hertelendi, Matthias Eiber, Oliver Sartor

Bibliographic record

VenueNuklearmedizin - NuclearMedicine · 2025
Typearticle
Languageen
FieldMedicine
TopicProstate Cancer Treatment and Research
Canadian institutionsBC Cancer Agency
Fundersnot available
KeywordsTaxaneProstate cancerMedicineOncologyInternal medicineQuality of life (healthcare)CastrationCancerBreast cancerHormoneNursing

Abstract

fetched live from OpenAlex

Ziel/Aim: In PSMAfore (NCT04689828), [ 177 Lu]Lu-PSMA-617 ( 177 Lu-PSMA-617) prolonged rPFS versus androgen receptor pathway inhibitor (ARPI) change in taxane-naive patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). We now present the time to symptomatic skeletal events (SSE) and time to worsening (TTW) in health-related quality of life (HRQoL) and pain at the third interim analysis (data cutoff, 27 Feb 2024). Methodik/Methods: Eligible patients had mCRPC, were candidates for ARPI change after one progression on previous ARPI, and had≥1 PSMA-positive and no exclusionary PSMA-negative metastatic lesions by [ 68 Ga]Ga-PSMA-11 PET/CT. Patients were randomized 1:1 to open-label 177 Lu-PSMA-617 (7.4 GBq q6w; 6 cycles) or ARPI change (abiraterone/enzalutamide). Patients with confirmed radiographic progression on ARPI change could cross over to 177 Lu-PSMA-617. The primary endpoint was rPFS. Other endpoints included time to SSE and TTW in self-reported HRQoL (FACT-P, EQ-5D-5L; secondary) and pain (BPI-SF; exploratory). Ergebnisse/Results: In total, 468 patients (234/arm) were randomized. Median duration of exposure was 8.4 months for 177 Lu-PSMA-617 and 6.5 months for ARPI change. 177 Lu-PSMA-617 prolonged time to SSE (27 [11.5%] vs 63 [26.9%]) and fewer bone fractures were reported versus ARPI change (4 [1.7%] vs 13 [5.6%]). 177 Lu-PSMA-617 prolonged TTW in FACT-P (7,46 [6.08, 8.54]vs 4.27 [3.45, 4.50]), EQ-5D-5L (6,28 [4.70, 7.86] vs 3.88 [3.25, 4.44]) and BPI-SF (5.13 [4.11, 6.14] vs 3.65 [3.05, 4.34]) versus ARPI change. Incidences of grade≥3 adverse events (AEs), serious AEs and AEs leading to discontinuation for 177 Lu-PSMA-617 and ARPI change were 36% and 48%, 20% and 32%, and 5.7% and 5.2%, respectively. Schlussfolgerungen/Conclusion: 177 Lu-PSMA-617 clinically meaningfully and significantly prolonged time to SSE and TTW in self-reported HRQoL and pain versus ARPI change in taxane-naive patients with PSMA-positive mCRPC. The presenter Prof. Matthias Eiber was not part of the original analysis (Original

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.016

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.001
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0030.003
Bibliometrics0.0000.001
Science and technology studies0.0010.001
Scholarly communication0.0010.001
Open science0.0010.000
Research integrity0.0020.004
Insufficient payload (model declined to judge)0.0030.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.028
GPT teacher head0.374
Teacher spread0.346 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractno

Explore more

Same venueNuklearmedizin - NuclearMedicineSame topicProstate Cancer Treatment and ResearchFrench-language works237,207